#NEWS: At #ESMO26, Amgen presents late-breaking data for our DLL3-targeting T-cell engager, with findings simultaneously published in @NEJM.

These landmark results add to our growing body of evidence across the #SCLC treatment journey.

Read more: https://amgen.ly/4zVJDcm
$AMGN